Halozyme To Participate In Upcoming Investor Conferences

Date : 06/04/2019 @ 1:00PM
Source : PR Newswire (US)
Stock : Halozyme Therapeutics Incorporated (HALO)
Quote : 16.32  -1.67 (-9.28%) @ 1:00AM
After Hours
Last Trade
Last $ 16.32 ◊ 0.00 (0.00%)

Halozyme To Participate In Upcoming Investor Conferences

Halozyme Therapeutics (NASDAQ:HALO)
Historical Stock Chart

1 Year : From Apr 2019 to Apr 2020

Click Here for more Halozyme Therapeutics Charts.

SAN DIEGO, June 4, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will participate in two upcoming investor conferences.

  • The Goldman Sachs 40th Annual Global Healthcare Conference on Wednesday, June 12 at 1:40 p.m. ET / 10:40 a.m. PT in Rancho Palos Verdes, CA. Dr. Helen Torley, president and chief executive officer, will represent the company in a question and answer session.
  • The JMP Securities Life Sciences Conference on Wednesday, June 19 at 2:30 p.m. ET / 11:30 a.m. PT in New York, NY.  Laurie Stelzer, senior vice president and chief financial officer, will represent the company in a question and answer session.

A live webcast of each session can be accessed through the "Investors" section of www.halozyme.com, and a recording will be made available for 90 days following each event. To access a live webcast, please visit Halozyme's website approximately 15 minutes prior to the presentation to register and download any necessary audio software.

About Halozyme

Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies that target the tumor microenvironment. Halozyme's lead proprietary program, investigational drug pegvorhyaluronidase alfa (PEGPH20), applies a unique approach to targeting solid tumors, allowing increased access of co-administered cancer drug therapies to the tumor in animal models. PEGPH20 is currently in development for the treatment of several cancers and has the potential to be used in combination with different types of cancer therapies. In addition to its proprietary product portfolio, Halozyme has established value-driving partnerships with leading pharmaceutical and biotechnology companies, including Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly, Bristol-Myers Squibb, Alexion and argenx, for its ENHANZE® drug delivery technology. Halozyme is headquartered in San Diego. For more information visit www.halozyme.com.

Al Kildani
Vice President, Investor Relations and Corporate Communications

Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.)


Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/halozyme-to-participate-in-upcoming-investor-conferences-300860923.html

SOURCE Halozyme Therapeutics, Inc.

Copyright 2019 PR Newswire

Latest HALO Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.